Search

Displaying results 5611 - 5620 of 8697 in total
  1. Drug

    Nitroarginine

    go.drugbank.com/drugs/DB04223
    Investigational

    An inhibitor of nitric oxide synthetase which has been shown to prevent glutamate toxicity. … Nitroarginine has been experimentally tested for its ability to prevent ammonia toxicity and ammonia-induced alterations in brain energy and ammonia metabolites. (Neurochem Res 1995:200(4):451-6)

  2. Drug

    Sinapultide

    go.drugbank.com/drugs/DB11332
    ApprovedWithdrawn

    [L2502] Windtree Therapeutics plans a phase III trial for Respiratory distress syndrome in 2018.

  3. Drug

    BB 21217

    go.drugbank.com/drugs/DB17373
    Investigational

    ) for memory-like T cells. … BB 21217 is an anti-BCMA CAR T cell therapy that uses the same CAR molecule as [idecabtagene vicleucel] (bb2121), but adds the PI3K inhibitor bb007 during ex vivo culture to enrich the drug product (DP

  4. Drug

    RGX-501

    go.drugbank.com/drugs/DB17639
    Investigational

    It is being investigated for the treatment of homozygous familial hypercholesterolemia.[L46696] … RGX-501 is an adeno-associated virus vector 8 (AAV8)-mediated gene therapy that delivers a functional copy of the human low-density lipoprotein receptor (LDLR) gene to liver cells.

  5. Drug

    Dabocemagene autoficel

    go.drugbank.com/drugs/DB17878
    Investigational

    Developed by Castle Creek Biosciences Inc., dabocemagene autoficel is being investigated for the treatment of dystrophic epidermolysis bullosa.[L46797] … Dabocemagene autoficel is an _ex vivo_, autologous cell-based gene therapy. It comprises autologous dermal fibroblasts genetically modified to express functional type VII collagen.

    Synonyms: TRANSDUCED HUMAN AUTOLOGOUS DYSTROPHIC EPIDERMOLYSIS BULLOSA DERMAL FIBROBLAST CELL FCX-007 INTEGRATED PROVIRAL HUMAN COLLAGEN TYPE VII TRANSGENE COL7A1 PLUS 5'-HUMAN CYTOMEGALOVIRUS PROMOTER/UTR-AND 3'-LTR/PO
  6. Drug

    Viralym-C

    go.drugbank.com/drugs/DB17975
    Investigational

    It was granted FDA orphan designation in January 2017 and investigated for the treatment of CMV infection.[A260291, L47241] … Viralym-C is an investigational T-cell immunotherapy developed by ViraCyte. It consists of Human Leukocyte Antigen (HLA)-matched cytomegalovirus (CMV)-specific T lymphocytes.

  7. Drug

    BO-653

    go.drugbank.com/drugs/DB19216
    Investigational

    BO-653 is under investigation in clinical trial NCT00055510 (A Blinded Study Conducted at Multiple Centers Evaluating Various Doses of an Investigational Agent (BO-653) Against Placebo, for Safety and

  8. Drug

    Medifoxamine

    go.drugbank.com/drugs/DB13219
    Approved

    Medifoxamine was marketed as an atypical antidepressant, with anxiolyitc properties in France, Spain, and Morrocco in the 1990s but was later withdrawn from the market due to it causing cases of hepatotoxicity

  9. Drug

    Phenylacetic acid

    go.drugbank.com/drugs/DB09269
    Approved

    Phenylacetic acid is an organic compound containing a phenyl functional group and a carboxylic acid functional group. It is a white solid with a disagreeable odor.

  10. Drug

    CR665

    go.drugbank.com/drugs/DB05155
    Experimental

    In preclinical studies, CR665 was highly selective for the peripheral kappa opioid receptor. Preclinical animal studies suggest that CR665 is a potent analgesic compound. … CR665 is the lead clinical development candidate from a series of highly selective peripheral kappa opioid receptor agonists.